Chemomab Therapeutics Ltd Financials

CMMB

Source SEC Filings (10-K/10-Q) Updated Jun 30, 2025 Currency USD FYE December

Financial Health Signals

Piotroski F-Score Weak

2/9

Chemomab Therapeutics Ltd passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

1.10x

For every $1 of reported earnings, Chemomab Therapeutics Ltd generates $1.10 in operating cash flow (-$15.4M OCF vs -$13.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

This page shows Chemomab Therapeutics Ltd (CMMB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Export CSV

Key Financial Metrics

Revenue

N/A

EBITDA

-$102.9M

Chemomab Therapeutics Ltd's EBITDA was -$102.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

Free Cash Flow

-$15.4M

YoY+34.8%

Chemomab Therapeutics Ltd generated -$15.4M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 34.8% from the prior year.

Net Income

-$13.9M

YoY+42.4%

Chemomab Therapeutics Ltd reported -$13.9M in net income in fiscal year 2024. This represents an increase of 42.4% from the prior year.

EPS (Diluted)

$0.04

YoY-62.1%

Chemomab Therapeutics Ltd earned $0.04 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 62.1% from the prior year.

Cash & Debt

$6.1M

YoY-34.7%

5Y CAGR-19.2%

Chemomab Therapeutics Ltd held $6.1M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

377M

YoY+32.7%

Chemomab Therapeutics Ltd had 377M shares outstanding in fiscal year 2024. This represents an increase of 32.7% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$11.3M

YoY-38.4%

5Y CAGR-3.2%

Chemomab Therapeutics Ltd invested $11.3M in research and development in fiscal year 2024. This represents a decrease of 38.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

YoY-100.0%

Chemomab Therapeutics Ltd invested $0 in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 100.0% from the prior year.

CMMB Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	$2.5M-43.9%	$4.4M-14.6%	$5.1M+55.3%	$3.3M	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$11.3M-38.4%	$18.4M+8.3%	$17.0M+168.0%	$6.3M+35.2%	$4.7M-64.8%	$13.3M
SG&A Expenses	$3.4M-51.8%	$7.1M-38.8%	$11.6M+91.5%	$6.0M+368.4%	$1.3M-79.4%	$6.2M
Operating Income	-$103.0M	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	$6K-33.3%	$9K
Income Tax	$0	$0+100.0%	-$534K	$0	$0	$0
Net Income	-$13.9M+42.4%	-$24.2M+12.4%	-$27.6M-121.6%	-$12.5M-109.7%	-$6.0M+78.1%	-$27.1M
EPS (Diluted)	$0.04-62.1%	$0.10-14.9%	$0.12+101.7%	$0.06	N/A	N/A

Metric	Q2'25	Q2'24	Q4'23	Q2'23	Q4'22	Q3'22	Q2'22	Q4'21
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$2.9M	N/A	$5.0M	N/A	$5.4M+86.1%	$2.9M	N/A
SG&A Expenses	N/A	$840K	N/A	$3.2M	N/A	$2.9M-13.4%	$3.3M	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	$0	N/A	$34K	N/A	$0+100.0%	-$544K	N/A
Net Income	-$2.1M+43.3%	-$3.6M	N/A	-$8.0M	N/A	-$8.1M-30.5%	-$6.2M	N/A
EPS (Diluted)	N/A	$0.01	N/A	$0.04	N/A	$0.04+29.6%	$0.03	N/A

CMMB Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$17.0M-23.4%	$22.2M-48.6%	$43.1M-33.1%	$64.4M+415.8%	$12.5M-36.8%	$19.8M
Current Assets	$16.0M-23.2%	$20.9M-49.9%	$41.7M-33.4%	$62.7M+429.5%	$11.8M-35.0%	$18.2M
Cash & Equivalents	$6.1M-34.7%	$9.3M-31.3%	$13.5M-11.0%	$15.2M+30.1%	$11.7M-33.6%	$17.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.4M-33.5%	$5.2M-24.6%	$6.8M+136.9%	$2.9M+72.5%	$1.7M-65.5%	$4.8M
Current Liabilities	$3.2M-33.5%	$4.8M-28.3%	$6.7M+154.7%	$2.6M+101.4%	$1.3M-68.1%	$4.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$13.5M-20.4%	$17.0M-53.1%	$36.2M-41.1%	$61.5M+469.0%	$10.8M-12.7%	$12.4M
Retained Earnings	-$102.6M-15.7%	-$88.7M-39.0%	-$63.8M-76.4%	-$36.2M-52.7%	-$23.7M+77.5%	-$105.4M

Metric	Q2'25	Q2'24	Q4'23	Q2'23	Q4'22	Q3'22	Q2'22	Q4'21
Total Assets	$11.1M-34.4%	$17.0M-23.4%	$22.2M-23.2%	$28.8M-33.0%	$43.1M-14.2%	$50.2M-10.9%	$56.4M-12.4%	$64.4M
Current Assets	$10.6M-33.8%	$16.0M-23.2%	$20.9M-24.6%	$27.7M-33.6%	$41.7M-14.3%	$48.7M-11.1%	$54.8M-12.5%	$62.7M
Cash & Equivalents	$5.4M-10.3%	$6.1M-34.7%	$9.3M-10.5%	$10.4M-23.2%	$13.5M+25.9%	$10.7M+8.7%	$9.9M-34.9%	$15.2M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.4M-58.3%	$3.4M-33.5%	$5.2M-24.8%	$6.9M+0.3%	$6.8M+22.3%	$5.6M+23.2%	$4.5M+57.3%	$2.9M
Current Liabilities	$1.4M-55.6%	$3.2M-33.5%	$4.8M-29.1%	$6.8M+1.1%	$6.7M+23.2%	$5.5M+24.6%	$4.4M+65.8%	$2.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$9.7M-28.4%	$13.5M-20.4%	$17.0M-22.7%	$22.0M-39.3%	$36.2M-18.8%	$44.6M-13.9%	$51.8M-15.7%	$61.5M
Retained Earnings	-$108.0M-5.2%	-$102.6M-15.7%	-$88.7M-10.1%	-$80.5M-26.2%	-$63.8M-14.9%	-$55.5M-17.0%	-$47.5M-31.2%	-$36.2M

CMMB Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$15.4M+34.8%	-$23.6M-15.9%	-$20.4M-64.6%	-$12.4M-136.1%	-$5.2M+68.1%	-$16.5M
Capital Expenditures	$0-100.0%	$3K-95.6%	$68K-71.5%	$239K+528.9%	$38K-60.0%	$95K
Free Cash Flow	-$15.4M+34.8%	-$23.6M-15.5%	-$20.4M-62.0%	-$12.6M-138.9%	-$5.3M+68.1%	-$16.6M
Investing Cash Flow	$2.3M-85.5%	$15.9M-18.7%	$19.5M+143.2%	-$45.2M-72780.6%	-$62K+34.7%	-$95K
Financing Cash Flow	$9.9M+181.6%	$3.5M+533.7%	-$808K-101.3%	$61.1M+1185.8%	$4.8M-82.2%	$26.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'25	Q2'24	Q4'23	Q2'23	Q4'22	Q3'22	Q2'22	Q4'21
Operating Cash Flow	N/A	N/A	N/A	-$7.5M-31.3%	-$5.7M-8.5%	-$5.3M+7.8%	-$5.7M-97.0%	-$2.9M
Capital Expenditures	N/A	N/A	N/A	$2K+100.0%	$1K-97.6%	$42K+281.8%	$11K-91.8%	$134K
Free Cash Flow	N/A	N/A	N/A	-$7.5M-31.3%	-$5.7M-7.7%	-$5.3M+7.3%	-$5.7M-88.6%	-$3.0M
Investing Cash Flow	N/A	N/A	N/A	-$4.3M-145.6%	$9.3M+53.9%	$6.1M+251.7%	$1.7M+108.8%	-$19.6M
Financing Cash Flow	N/A	N/A	N/A	$1.4M+257.4%	-$869K-2328.2%	$39K+77.3%	$22K+127.2%	-$81K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CMMB Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-82.2%+27.1pp	-109.3%-45.1pp	-64.2%-44.8pp	-19.4%+28.3pp	-47.7%+89.6pp	-137.3%
Current Ratio	4.98+0.7	4.32-1.9	6.18-17.5	23.66+14.7	9.00+4.6	4.42
Debt-to-Equity	0.25-0.1	0.30+0.1	0.19+0.1	0.05-0.1	0.15-0.2	0.39
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'25	Q2'24	Q4'23	Q2'23	Q4'22	Q3'22	Q2'22	Q4'21
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-18.5%+6.5pp	-25.0%	N/A	-27.6%	N/A	-16.1%-5.1pp	-11.0%	N/A
Current Ratio	7.42+2.4	4.98+0.7	4.32+0.3	4.06-2.1	6.18-2.7	8.90-3.6	12.48-11.2	23.66
Debt-to-Equity	0.15-0.1	0.25-0.1	0.300.0	0.31+0.1	0.19+0.1	0.13+0.0	0.09+0.0	0.05
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Tharimmune Inc THAR

$177.1M

Longeveron Inc LGVN

$11.4M

Minerva Neurosci NERV

$271.3M

Cocrystal Pharma Inc COCP

$13.3M

Edesa Biotech Inc EDSA

$8.5M

Frequently Asked Questions

Is Chemomab Therapeutics Ltd profitable?

No, Chemomab Therapeutics Ltd (CMMB) reported a net income of -$13.9M in fiscal year 2024.

What is Chemomab Therapeutics Ltd's earnings per share (EPS)?

Chemomab Therapeutics Ltd (CMMB) reported diluted earnings per share of $0.04 for fiscal year 2024. This represents a -62.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Chemomab Therapeutics Ltd's EBITDA?

Chemomab Therapeutics Ltd (CMMB) had EBITDA of -$102.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Chemomab Therapeutics Ltd's free cash flow?

Chemomab Therapeutics Ltd (CMMB) generated -$15.4M in free cash flow during fiscal year 2024. This represents a 34.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Chemomab Therapeutics Ltd's operating cash flow?

Chemomab Therapeutics Ltd (CMMB) generated -$15.4M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Chemomab Therapeutics Ltd's total assets?

Chemomab Therapeutics Ltd (CMMB) had $17.0M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Chemomab Therapeutics Ltd's capital expenditures?

Chemomab Therapeutics Ltd (CMMB) invested $0 in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Chemomab Therapeutics Ltd spend on research and development?

Chemomab Therapeutics Ltd (CMMB) invested $11.3M in research and development during fiscal year 2024.

How many shares does Chemomab Therapeutics Ltd have outstanding?

Chemomab Therapeutics Ltd (CMMB) had 377M shares outstanding as of fiscal year 2024.

What is Chemomab Therapeutics Ltd's current ratio?

Chemomab Therapeutics Ltd (CMMB) had a current ratio of 4.98 as of fiscal year 2024, which is generally considered healthy.

What is Chemomab Therapeutics Ltd's debt-to-equity ratio?

Chemomab Therapeutics Ltd (CMMB) had a debt-to-equity ratio of 0.25 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Chemomab Therapeutics Ltd's return on assets (ROA)?

Chemomab Therapeutics Ltd (CMMB) had a return on assets of -82.2% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Chemomab Therapeutics Ltd's cash runway?

Based on fiscal year 2024 data, Chemomab Therapeutics Ltd (CMMB) had $6.1M in cash against an annual operating cash burn of $15.4M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Chemomab Therapeutics Ltd's Piotroski F-Score?

Chemomab Therapeutics Ltd (CMMB) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Chemomab Therapeutics Ltd's earnings high quality?

Chemomab Therapeutics Ltd (CMMB) has an earnings quality ratio of 1.10x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.